Evidence map›Paper›PMID 37707952›Full record

ArticleJCI insight2023

Itaconate-producing neutrophils regulate local and systemic inflammation following trauma.

Janna L Crossley, Sonya Ostashevskaya-Gohstand, Stefano Comazzetto, Jessica S Hook, Lei Guo, Neda Vishlaghi, Conan Juan, Lin Xu, Alexander R Horswill, Gerta Hoxhaj and 3 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Itaconate and its derivatives in human health and diseases.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Galectin-9Aging cell · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Janna L CrossleyDepartment of Surgery.
Sonya Ostashevskaya-GohstandDepartment of Surgery.
Stefano ComazzettoChildren's Research Institute and Department of Pediatrics.
Jessica S HookDepartment of Pediatrics, and.
Lei GuoQuantitative Biomedical Research Center, Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA.
Neda VishlaghiDepartment of Surgery.
Conan JuanDepartment of Surgery.
Lin XuDepartment of Pediatrics, and.
Alexander R HorswillDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Gerta HoxhajChildren's Research Institute and Department of Pediatrics.
Jessica G MorelandDepartment of Pediatrics, and.
Robert J TowerDepartment of Surgery.
Benjamin LeviDepartment of Surgery.
The University of Texas Southwestern Medical Center · USChildren’s Institute · USPediatrics and Genetics · USSouthwestern Medical Center · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Targeting jmjd3 mitigates heterotopic ossificationR01AR079863 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Katherine Ann Gallagher, Benjamin Levi · 2021 to 2026
$3.0M
Neutrophil Biomarker and neutrophil targeted therapy to predict and prevent heterotopic ossificationR61AR078072 · NIAMS · UT SOUTHWESTERN MEDICAL CENTER · PI LEVI, BENJAMIN · 2020 to 2021
$786k
NIAMS NIH HHS R01 AR079863NIAMS NIH HHS R61 AR078072
6 · The paper itself

Abstract

Modulation of the immune response to initiate and halt the inflammatory process occurs both at the site of injury as well as systemically. Due to the evolving role of cellular metabolism in regulating cell fate and function, tendon injuries that undergo normal and aberrant repair were evaluated by metabolic profiling to determine its impact on healing outcomes. Metabolomics revealed an increasing abundance of the immunomodulatory metabolite itaconate within the injury site. Subsequent single-cell RNA-Seq and molecular and metabolomic validation identified a highly mature neutrophil subtype, not macrophages, as the primary producers of itaconate following trauma. These mature itaconate-producing neutrophils were highly inflammatory, producing cytokines that promote local injury fibrosis before cycling back to the bone marrow. In the bone marrow, itaconate was shown to alter hematopoiesis, skewing progenitor cells down myeloid lineages, thereby regulating systemic inflammation. Therapeutically, exogenous itaconate was found to reduce injury-site inflammation, promoting tenogenic differentiation and impairing aberrant vascularization with disease-ameliorating effects. These results present an intriguing role for cycling neutrophils as a sensor of inflammation induced by injury - potentially regulating immune cell production in the bone marrow through delivery of endogenously produced itaconate - and demonstrate a therapeutic potential for exogenous itaconate following tendon injury.

Indexed as

NeutrophilsSuccinatesHumansInflammationMacrophagesitaconic acidSuccinatesImmunologyInflammationNeutrophils

Identifiers

PMID37707952
PMCPMC10619500
OpenAlexW4386741913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.